Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2892360 | 0.98 | HRH1 (0.57) | HRH1LOXL2NAAAHRH3HRH4 | |
| SCHEMBL9466820 | 0.98 | HRH1 (0.63) | HRH1LOXL2NAAAHRH3HRH4 | |
| SCHEMBL7417903 | 0.98 | HRH1 (0.63) | HRH1LOXL2NAAAHRH3HRH4 | |
| SCHEMBL742971 | 0.93 | HRH1 (0.56) | HRH1LOXL2NAAAHRH3HRH4 | |
| Hydrochloric Acid SCHEMBL1869293 | 0.91 | HRH1 (0.54) | HRH1LOXL2NAAAHRH3HRH4 | |
| SCHEMBL10386360 | 0.88 | HRH1 (0.53) | HRH1NAAACYP3A4ALDH1A1HSD17B10 | |
| SCHEMBL726645 | 0.87 | HRH1 (0.73) | HRH1LOXL2NAAAHRH3HRH4 | |
| SCHEMBL12050755 | 0.87 | CYP17A1 (0.47) | HRH1LOXL2NAAACYP3A4CYP2D6 | |
| SCHEMBL4413800 | 0.85 | HRH1 (0.77) | HRH1LOXL2NAAAHRH3HRH4 | |
| SCHEMBL2841394 | 0.85 | HRH1 (0.77) | HRH1LOXL2NAAAHRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111233748-B | Synthesis of tirofiban hydrochloride | 江苏慧聚药业股份有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-111100066-B | Tirofiban hydrochloride intermediate and preparation method of Tirofiban hydrochloride | 石药集团恩必普药业有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-111233748-A | Synthesis of tirofiban hydrochloride | 海门慧聚药业有限公司 | 2020-06-05 | — | — | CN | disclosed |
| CN-111138349-A | Synthesis method of tirofiban hydrochloride intermediate III | 鲁南制药集团股份有限公司 | 2020-05-12 | — | — | CN | disclosed |
| CN-111100066-A | Tirofiban hydrochloride intermediate and preparation method of Tirofiban hydrochloride | 石药集团恩必普药业有限公司 | 2020-05-05 | — | — | CN | disclosed |
| CN-102452975-A | Synthesis method of tirofiban hydrochloride intermediate | TIANJIN KANGHONG MEDICAL TECHNOLOGY DEV CO LTD | 2012-05-16 | — | — | CN | disclosed |
| CN-102285912-A | Method for preparing N-n-butylsulfonyl-O-(4-(4-pyridyl)-butyl)-L-tyrosine alkyl ester | — | 2011-12-21 | — | — | CN | disclosed |
| US-7772229-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, (SE) | 2009-12-31 | — | — | US | disclosed |
| EP-1330452-B1 | PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES | ORTHO MCNEIL PHARM INC (US) | 2008-11-26 | — | — | EP | disclosed |
| US-5206373-A | Process for preparing fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1993-04-27 | — | — | US | disclosed |
| US-5206233-A | Antidepressants, antiischemic agents | WARNER-LAMBERT COMPANY (US) | 1993-04-27 | — | — | US | disclosed |
| WO-1993004053-A1 | SUBSTITUTED THIAZEPINES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5187280-A | Dopaminergic, antipsychotic and antihypertensive agents | WARNER-LAMBERT COMPANY (US) | 1993-02-16 | — | — | US | disclosed |
| US-5118691-A | Substituted tetrahydropyridines as central nervous system agents | WARNER-LAMBERT CO. (US) | 1992-06-02 | — | — | US | disclosed |
| US-5045550-A | Antipsychotic, hypotensive agents, dopaminergic | WARNER-LAMBERT CO. (US) | 1991-09-03 | — | — | US | disclosed |
| EP-0101381-B1 | ANOREXIC TRIFLUOROMETHYL PHENYL TETRAHYDROPYRIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI S.A. (FR) | 1985-12-04 | — | — | EP | disclosed |
| US-4521428-A | Anorexigenic trifluoromethylphenyltetrahydropyridines and pharmaceutical compositions containing them | SANOFI (FR) | 1985-06-04 | — | — | US | disclosed |
| EP-0101381-A1 | Anorexic trifluoromethyl phenyl tetrahydropyridines, process for their preparation and pharmaceutical compositions containing them | SANOFI S.A. (FR) | 1984-02-22 | — | — | EP | disclosed |
| US-4203987-A | HYPOTENSIVE AGENTS, ANTISECRETORY AGENTS, ANTIULCER AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, SCN1B | HRH1 970/4885LOXL2 3672/4885NAAA 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.